PROSIDION LIMITED SCIENTIFIC ADVISORY BOARD AND CONSULTING AGREEMENTScientific Advisory Board and Consulting Agreement • February 27th, 2009 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • England and Wales
This Scientific Advisory Board and Consulting Agreement (this “Agreement”) is made and entered into as of December 16, 2008, and effective as of January 1, 2009 (the “Effective Date”), by and between Prosidion Limited, a company registered in England and Wales under registered number 4600121 with its registered office at Watlington Road, Oxford, UK OX4 6LT (the “Company”) and Dr. Daryl Granner, Professor, an individual with an address of 707 Light Hall, Vanderbilt University Medical Centre, Nashville, Tennessee 37232, USA (“Consultant ”).
PROSIDION LIMITED LETTERHEAD]Scientific Advisory Board and Consulting Agreement • January 29th, 2007 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
RECITALSScientific Advisory Board and Consulting Agreement • March 8th, 2005 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • England and Wales
NanoViricides, Inc. SCIENTIFIC ADVISORY BOARD AND CONSULTING AGREEMENTScientific Advisory Board and Consulting Agreement • November 14th, 2006 • Nanoviricides, Inc.
THIS SCIENTIFIC ADVISORY BOARD AND CONSULTING AGREEMENT (the “Agreement”), made this day of ("the Effective Date"), is entered into by Nanoviricide, Inc., a Florida corporation with its principal place of business at 135 Wood Street, West Haven, CT 06516 (the “Company”), and (the “Consultant”).
Dr Daryl Granner Vanderbilt University Medical Centre 707 Light Hall Nashville Tennessee 37232 USA 1st January 2008 Dear Sirs Scientific Advisory Board and Consulting Agreement, dated as of 10th February 2006 between Prosidion Limited and Dr Daryl...Scientific Advisory Board and Consulting Agreement • February 28th, 2008 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
This letter will serve as notice of our desire to renew the term of the Agreement for an additional twelve-month period, from 1st January 2008 through to 31st December 2008. All other terms and conditions of the Agreement will remain in full force and effect.
